Articles tagged with Cancer Medication
Breast cancers with high androgen receptor (AR) levels are more likely to relapse after estrogen-targeting therapies. Anti-androgen therapy shows promising responses in cell lines and preclinical models, offering a new potential target for breast cancer treatment.
The study found that while the program was rarely used, those who participated reported gratitude for receiving a lethal prescription, regardless of use. The most common reasons for participation included loss of autonomy, inability to engage in enjoyable activities, and loss of dignity. SCCA's approach prioritizes palliative care and ...
A new class of tumor-fighting drugs using RNA interference has shown promising safety and efficacy in a clinical trial. The study found that the drug acts by silencing the PLK1 gene involved in tumor growth and can be safely administered in humans, with most patients tolerating it well and some showing therapeutic benefit.
A genetic biomarker, MYCN amplification, has been identified as a potential target for a new class of anti-cancer drugs in neuroblastoma patients. The study found that tumors with excess copies of the gene were highly sensitive to BET bromodomain inhibitors, leading to impaired cell growth and induction of cell death.
Researchers found that the drug combination resulted in a 70% decrease in tumor volume compared to single-drug treatment. The study suggests that MK-1775 and gemcitabine may represent a novel approach in treating sarcomas, offering new hope for rare cancer patients.
A new study found that one-quarter of women who need hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course. Side effects were cited as the most common reason for skipping treatment.
Researchers found that Mer receptor overexpression correlates with melanoma progression and aggressiveness, driving disease severity. Investigational drug UNC1062 blocks Mer survival signaling, killing melanoma cells in dishes and mouse models.
Researchers at Penn Medicine discovered that cells with low helicase-like transcription factor (HLTF) expression are more likely to respond to autophagy inhibition. This finding could lead to the development of a predictive biomarker for patients who may benefit from this treatment approach.
The novel inhibitor XL-184 (Cabozantinib) showed significant tumor growth decrease in 12 colorectal cancer explants, with 8 exhibiting stable disease. The drug targets both VEGFR2 signaling pathway and c-MET for survival of tumor cells.
A subset of breast cancer patients with HER-2 positive tumors may benefit from a combination of targeted treatments that avoid chemotherapy. The study, published in the Journal of Clinical Oncology, shows high efficacy in eradicating tumors and offers a groundbreaking approach to treatment without significant side effects.
A new study found that long-term use of arrhythmia medication amiodarone may significantly increase the risk of developing certain cancers. Men and individuals taking high cumulative daily doses were more likely to develop cancer, with a 46% increased risk compared to those taking low doses.
A phase 1 clinical trial found that a combination of sapacitabine and seliciclib showed anti-cancer activity in patients with incurable solid tumors and inherited BRCA mutations. The treatment demonstrated partial responses in four patients, stable disease for over a year in three others.
Researchers found that combining non-steroidal anti-inflammatory drugs with cholesterol-lowering medication Lipitor can effectively prevent colorectal adenomas in mice. In contrast, the same combination was only effective when administered to mice with existing tumors.
Researchers found that Paragazole increases the sensitivity of triple-negative breast cancer cells to chemotherapy by inducing expression of estrogen receptors. The drug outperforms chemotherapy alone in a range of breast cancer cell lines, offering new hope for treatment options.
A phase I trial involving 29 patients with platinum-resistant ovarian cancer found one complete response and four partial responses to the antibody-drug conjugate DMUC5754A. The drug targets high-expression MUC16 protein in ovarian cancer cells, reducing adverse effects on healthy tissues.
Agios research shows that mutant IDH1 and IDH2 inhibitors can reverse cellular differentiation in patient-derived tumor samples, reducing the oncometabolite 2-HG levels. This provides promising preclinical support for targeted therapies against cancer-causing mutations.
The CTC-iChip system rapidly produces a purified solution of tumor cells for pathological and molecular analysis. This technology enables the analysis of single metastatic cells, providing insights into cancer evolution and metastasis.
Researchers found that SPOP mutations allow SRC-3 to proliferate and spread prostate cancer cells. The loss of SPOP's tumor-suppressing function enables SRC-3's cancer-promoting effects, making it an important target for prostate cancer treatment.
A new study finds that frequent use of the gastroesophageal reflux disease label in infants leads to overuse of medication, causing needless expenses for families. The researchers concluded that parents' expectations of medication are driven by the doctor's words, which can make a normal process seem like a disease.
Dana-Farber scientists have identified a novel glutamine pathway that fuels the growth and spread of pancreatic cancer cells, which may be vulnerable to targeted drugs. The research suggests that inhibiting this pathway could make tumors more susceptible to standard treatments without harming healthy tissues.
A study published in JAMA Psychiatry found that varenicline significantly improved abstinence rates compared to bupropion and placebo. Smokers who took varenicline experienced better emotional functioning and lower levels of sadness, regardless of whether they abstained from smoking or not.
Ganetespib shows greater antitumor activity against ALK-positive NSCLC and overcomes crizotinib resistance in mice xenografted with human cancer cells. The drug is effective for treating patients who have become resistant to FDA-approved targeted therapy.
University of Montreal researchers found that metformin reduces the production of inflammatory cytokines, which can lead to pathological inflammation and cancer growth. The study suggests that metformin may slow down the aging process by preventing this chronic inflammation.
A team from Wake Forest Baptist Medical Center's Institute for Regenerative Medicine has developed engineered ovaries that can sustainably release sex hormones estrogen and progesterone. The bioartificial ovary could potentially replace hormone drugs, offering a more natural approach to hormone replacement therapy.
Researchers found that different mutations in the same gene may require different treatments for child brain tumors. A new study identified a second-generation BRAF inhibitor that targets specific mutations, offering hope for personalized medicine.
A new chemotherapy drug, arsenic trioxide, has been developed to be less toxic to female fertility while being more effective against cancer. The drug is packed into a nanobin, a tiny Trojan horse that delivers the drug directly to tumor cells.
A national survey of health professionals found that cancer drug shortages disrupt chemotherapy administration, increase costs, and add to the risk of adverse patient outcomes. The survey, conducted by St. Jude Children's Research Hospital, reports that 98% of respondents experienced a shortage in the previous year.
A new imaging dye has been shown to effectively detect and map cancers in lymph nodes, improving staging accuracy. The radioactive dye successfully identified cancerous lymph nodes, detecting 94% of malignancies compared to the standard blue dye's 76%.
A peptide derived from Pacific cod may prevent cancer cells from attaching to blood vessel walls and boost the immune response. The study suggests this natural protein could be a promising anti-metastatic agent for various cancers.
Researchers have discovered a set of genes that can predict which women are at high risk for estrogen-sensitive breast cancer, making it possible to identify potential beneficiaries of preventive drugs. The study identifies 13 genes associated with lipid or fat metabolism in women with hormone receptor-negative breast cancer.
Scientists warn millions in Asia may be at risk of kidney failure and bladder cancer from taking widely available herbal medicines. A new study proposes protocols for diagnosis and treatment, and suggests a need for better regulation to prevent exposure.
Researchers at the University of New Mexico Cancer Center have identified a first-in-class chemical compound, CID2950007, that inhibits Cdc42 GTPase activity, controlling cell migration and adhesion. This novel compound shows promise in preventing cancer metastasis and may also be effective against infectious diseases.
A new human monoclonal antibody, ESK1, has been developed to target proteins associated with many types of cancer, including leukemia and breast cancer. The antibody recognizes a protein called WT1, which is overexpressed in these cancers, and can kill cancer cells in preclinical research.
Researchers identified an enzyme that removes ADP-ribose modifications from proteins, essential for normal cell function. This finding provides a new pathogenic mechanism for neurodegenerative disorders and may lead to the development of new cancer drugs.
A new protein Smad7 has been found to protect against and heal mouth sores commonly associated with cancer treatment. The protein was administered genetically or topically to mouse models, resulting in dramatic resistance to oral mucositis development.
A new type of retinoblastoma has been discovered, driven by an oncogene, and is found in babies with no family history. The cancer starts long before birth and can be identified through molecular diagnostics.
Researchers have discovered a single anti-ageing enzyme that can be targeted by all 117 tested drugs, leading to a new class of anti-ageing medications. The enzymes' activators, such as resveratrol, show promising results in trials for various diseases, including cancer, diabetes and Alzheimer's.
A clinical trial comparing two treatments for advanced head and neck cancer found that adding a targeted biologic therapy to chemotherapy did not improve patient outcomes. The study's results suggest that the current standard of care therapy may be sufficient, at least for now.
A large European study found that eating processed meat was associated with an increased risk of premature death, particularly from cancer and cardiovascular disease. The researchers estimated that up to 3% of premature deaths could be prevented if people consumed less than 20g of processed meat per day.
Researchers have developed a new focal laser ablation treatment that uses precisely targeted heat to burn away cancerous cells in the prostate. The approach has shown promising safety results and can be performed without significant side effects.
A comprehensive computer model of human metabolism has been developed, connecting the dots between the human genome and metabolism. The Recon 2 model advances understanding of human metabolism in health and disease, enabling identification of biomarkers and prediction of drug side effects.
Researchers have discovered how oxidative stress can turn a benign cellular protein into a powerful accomplice in neuronal death. This finding could lead to new therapeutic approaches for debilitating diseases, including those related to inflammation, aging and amyotrophic lateral sclerosis.
Swedish scientists developed theranostic nanoparticles that can deliver chemotherapy to breast cancer cells while being detectable in MR scanners. The particles are biodegradable and show no toxicity, making them a potential tool against cancer.
Bioengineering researchers at UC Santa Barbara found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more effective at targeting and delivering anti-cancer drugs to breast cancer cells. The rod-shaped nanoparticles were engineered with an antibody called trastuzumab t...
Researchers at VCU Massey Cancer Center have developed a novel immunotherapy that could work like a vaccine against metastatic cancers. The therapy, called Flagrp-170, uses a molecule engineered to stimulate the immune system and attack cancer cells, with promising results in animal models.
A new University of Michigan study found that the protein HER2 plays a role even in breast cancers traditionally classified as HER2-negative. The research suggests that the drug Herceptin may have a greater impact on treating breast cancer and preventing its spread, particularly when given early to prevent tumor recurrence.
A Missouri survey found that 65% of tanning salon operators would allow children aged 10-12 to use tanning beds, despite evidence showing a link between tanning bed use and an increased risk of skin cancers. Many employees claimed no risks or benefits from indoor tanning, but these claims are false.
Researchers at the University of Wisconsin-Madison have developed a new technique to accelerate protein analysis, allowing for the simultaneous identification of proteins in multiple samples. This breakthrough could lead to faster diagnosis of cancer and the discovery of novel drug targets.
Researchers at Karolinska Institutet have discovered a new pseudogene that regulates the tumour-suppressing PTEN gene, enabling its potential reversal. This finding could lead to more effective cancer treatments by reprogramming cancer cells and preventing resistance.
Scientists found that distinct niches exist in bone marrow to nurture different types of blood stem cells, which could improve the success of stem cell transplants and chemotherapy. The discovery suggests that targeting specific support cells may be therapeutic for treating certain cancers.
Researchers have identified a biomarker that may identify neuroblastomas sensitive to BET bromodomain inhibitors. Neuroblastoma cells with MYCN amplification were found to be sensitive to these drugs in preclinical studies. The discovery offers new hope for treating this devastating childhood cancer.
Dr. Lewis Cantley, a pioneer in cancer research, has made significant breakthroughs in understanding the PI3K pathway and its role in cancer development. His work has led to revolutionary treatments and continues to advance precision medicine for cancer diagnosis and treatment.
Researchers at UC Riverside have developed a compound called TIR-199 that targets the proteasome complex in kidney cancer cells, showing promising results in laboratory tests. The compound is nearly as potent as existing bortezomib but selectively inhibits growth of only renal cancer cell lines.
Increased regulatory barriers and limited research funding hinder the development of effective treatments for childhood cancer. The authors call for renewed collaboration among industry, academia, governments, and patient advocacy to accelerate the discovery of new medicines for this devastating disease.
Acupuncture showed statistically significant improvements in symptoms and medication use for patients with seasonal allergic rhinitis. Increasing CT screening thresholds could decrease false positive results but may delay cancer diagnosis. The American College of Physicians has released a new tip sheet with these findings.
Researchers have identified an Indian plant compound, gedunin, that attacks a co-chaperone of Hsp90 and leads to the inactivation of the Hsp90 machine, killing cancer cells. This finding may open new ways for targeting Hsp90 using established inhibitors.
Researchers at Johns Hopkins Kimmel Cancer Center create cell lines from patients' own tumors to predict chemotherapy sensitivity. The new method may replace current laboratory tests and improve drug selection accuracy.
Emerging cancer drugs targeting tumor cells may also stimulate osteoclasts to tear down bone, increasing the risk of tumor spread. Researchers recommend closely monitoring patients' bone health when taking these drugs.
Researchers at Rice University propose combining synthetic and natural toxins to create a 'one-two punch' therapy against cancer and drug-resistant bacteria, potentially reducing side effects and preventing resistance. The approach targets the unique membranes of both cancer cells and Gram-negative bacteria.
A Phase I clinical trial demonstrated the therapeutic effect of RNAi gene silencing in treating advanced cancer patients. The drug, ALN-VSP, presented good evidence for clinical utility and showed significant tumor response in 11 out of 37 patients.